Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns [Yahoo! Finance]
Oric Pharmaceuticals, Inc. (ORIC)
Company Research
Source: Yahoo! Finance
secondary hematologic malignancy concerns in a confirmatory study, prompting questions about similar mechanisms in oncology. Oric has emphasized that its PRC2 inhibitor rinzimetostat is mechanistically distinct from Tazverik and has shown no malignancies in animal toxicity studies, a point several analysts highlight as they reaffirm confidence in the company's oncology pipeline and upcoming clinical data. Against this backdrop and a 7-day share price decline, we'll explore how safety differentiation for rinzimetostat shapes Oric's investment narrative. We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. What Is ORIC Pharmaceuticals' Investment Narrative? To own Oric Pharmaceuticals today, you have to believe that its epigenetic and targeted oncology pipeline, led by PRC2 inhibitor rinzimetostat and EGFR inhibitor enozertinib, can eventually translate clean early signals into registrational trials and, later on, r
Show less
Read more
Impact Snapshot
Event Time:
ORIC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORIC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORIC alerts
High impacting Oric Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ORIC
News
- ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswire
- A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Oric Pharmaceuticals (ORIC) had its "overweight" rating reaffirmed by Cantor Fitzgerald.MarketBeat
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright [Yahoo! Finance]Yahoo! Finance
ORIC
Earnings
- 2/23/26 - Beat
ORIC
Sec Filings
- 2/26/26 - Form 4
- 2/24/26 - Form 144
- 2/23/26 - Form 8-K
- ORIC's page on the SEC website